Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib +Programmed Cell Death Protein 1 (PD-1) Antibody in the Conversion-resection of Advanced Unresectable Hepatocellular Carcinoma:a Multicenter Prospective Cohort Study

NCT04997850 is registered in ClinicalTrials.gov with Xinrui Zhu，MD as lead sponsor.

NCT NCT04997850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04997850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib +Programmed Cell Death Protein 1 (PD-1) Antibody in the Conversion-resection of Advanced Unresectable Hepatocellular Carcinoma:a Multicenter Prospective Cohort Study
Lead sponsor
Xinrui Zhu，MD
Phase
Phase 1/2
Overall status
Completed
Start date
October 1, 2020
Completion date
January 31, 2024
Enrollment
142 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma non-resectable, immune checkpoint blockade, transarterial chemoembolization, tyrosine kinase inhibitor